Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Pinto Á
  • Reig O
  • Iglesias C
  • Gallardo E
  • García-Del Muro X
  • Alonso T
  • Anguera G
  • Suárez C
  • Villalobos-León L
  • Rodríguez-Sánchez Á
  • Lainez N
  • Martínez-Ortega E
  • Campayo M
  • Velastegui A
  • Rodriguez-Vida A
  • Villa-Guzmán JC
  • Méndez-Vidal MJ
  • Rubio G
  • García I
  • Capdevila L
  • Lambea J
  • Vázquez S
  • Fernández O
  • Hernando-Polo S
  • Cerezo S
  • Santander C
  • García-Marrero R
  • Zambrana F
  • González-Del Alba A
  • Lazaro-Quintela M
  • Castellano D
  • Chirivella I
  • Anido U
  • Viana A
  • García A
  • Sotelo M
  • Arévalo MG
  • García-Donas J
  • Hernández C
  • Bolós MV
  • Llinares J
  • Climent MA

Abstract

Axitinib monotherapy obtained approval in pre-treated mRCC patients and recently in combination with pembrolizumab or avelumab in the first-line setting. However, patient profiles that may obtain increased benefit from this drug and its combinations still need to be identified.

Copyright © 2021 Elsevier Inc. All rights reserved.

Datos de la publicación

ISSN/ISSNe:
1558-7673, 1938-0682

Clinical Genitourinary Cancer  CIG MEDIA GROUP, LP

Tipo:
Article
Páginas:
25-34
PubMed:
34789409
Factor de Impacto:
0,850 SCImago
Cuartil:
Q1 SCImago

Citas Recibidas en Web of Science: 3

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Axitinib, Renal cell carcinoma, Standard of care, Tyrosine kinase inhibitors, Vascular endothelial growth factor

Cita

Compartir